

BEST AVAILABLE COPY

10/8/4/98
updated search
L/Cook 6/5/06

d his

(FILE 'HOME' ENTERED AT 10:00:26 ON 05 JUN 2006)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, JAPIO' ENTERED AT 10:00:39 ON 05
JUN 2006

L1 18031 S PHOSPHOCHOLINE?
L2 14387 S PHOSPHORYLCHOLINE?
L3 2628 S L1 AND (PLATELET ACTIVATING FACTOR)
L4 1252 S L2 AND (PLATELET ACTIVATING FACTOR)
L5 89 S L3 AND ANTIBOD?
L6 56 S L4 AND ANTIBOD?
L7 34 DUPLICATE REMOVE L5 (55 DUPLICATES REMOVED)
L8 32 DUPLICATE REMOVE L6 (24 DUPLICATES REMOVED)
L9 22 S L7 AND PD<1998
L10 20 S L8 AND PD<1998
L11 0 S L9 AND L10
L12 3076 S (PLATELET ACTIVATING FACTOR) AND ANTIBOD?
L13 56 S L12 AND L2

=>

d his

(FILE 'HOME' ENTERED AT 10:00:26 ON 05 JUN 2006)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, JAPIO' ENTERED AT 10:00:39 ON 05
JUN 2006

L1 18031 S PHOSPHOCHOLINE?
L2 14387 S PHOSPHORYLCHOLINE?
L3 2628 S L1 AND (PLATELET ACTIVATING FACTOR)
L4 1252 S L2 AND (PLATELET ACTIVATING FACTOR)
L5 89 S L3 AND ANTIBOD?
L6 56 S L4 AND ANTIBOD?
L7 34 DUPLICATE REMOVE L5 (55 DUPLICATES REMOVED)
L8 32 DUPLICATE REMOVE L6 (24 DUPLICATES REMOVED)
L9 22 S L7 AND PD<1998
L10 20 S L8 AND PD<1998
L11 0 S L9 AND L10
L12 3076 S (PLATELET ACTIVATING FACTOR) AND ANTIBOD?
L13 56 S L12 AND L2

=>

ANSWER 18 OF 22 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1990:589360 CAPLUS

DN 113:189360

ED Entered STN: 23 Nov 1990

TI Antibodies to platelet-activating factor

AU Karasawa, Ken; Satoh, Noriko; Hongo, Toshio; Setaka, Morio; Mowri, Hiroomi; Takano, Tatsuya; Hashimoto, Shunichi; Ikegami, Shiro; Fujita, Kagari; et al.

CS Fac. Pharm. Sci., Teikyo Univ., Sagamiko, 199-01, Japan

SO Trends Pharmacol. Res. Platelet Act. Factor (PAF) Jpn., Proc. Symp. Probl. PAF, 11th (1988), Meeting Date 1987, 138-46. Editor(s): Ogura, Yasumi; Kisara, Kensaku. Publisher: Ishiyaku EuroAmerica, Tokyo, Japan.

CODEN: 56ULA2

DT Conference

LA English

CC 15-3 (Immunochemistry)

AB Specific antibodies to platelet-activating factor (PAF) were prepared by immunizing rabbits with a hapten-bovine serum albumin (BSA) conjugate. As hapten a synthetic PAF derivative was used which is resistant to enzymic inactivation by plasma or tissues and which can bind to BSA through covalent bonding at the ω -position of the alkyl side chain. Antibody activity was determined by ELISA. Anti-PAF IgG reacted strongly with PAF. By means of the ELISA inhibition assay, antibodies did not cross-react with phosphocholine glycerophosphocholine, dilaurylglycerophosphocholine, or PAF analogs which have ethanolamine-type polar head groups instead of choline groups. The monoclonal antibodies were also produced in Balb/c mouse using the same immunizing method. When PAF was incubated with monoclonal antibodies and protein A Sepharose, supernatant did not cause rabbit platelet aggregation. The specificity and sensitivity of the mouse monoclonal antibodies were compared with those of rabbit polyclonal antibodies.

ST platelet activating factor antibody

IT Immunoglobulins

RL: FORM (Formation, nonpreparative)
(G, formation of, to platelet-activating factor, synthetic hapten induction of)

IT Antibodies

RL: FORM (Formation, nonpreparative)
(monoclonal, formation of, to platelet-activating factor, synthetic hapten induction of)

IT 65154-06-5, Blood platelet-activating factor

RL: BIOL (Biological study)
(antibodies to, synthetic analog hapten in formation of)

IT 130126-32-8

RL: BIOL (Biological study)
(as hapten for antibody formation to platelet-activating factor)

AN 1990:589360 CAPLUS

DN 113:189360

ED Entered STN: 23 Nov 1990

TI Antibodies to platelet-activating factor

AU Karasawa, Ken; Satoh, Noriko; Hongo, Toshio; Setaka, Morio; Mowri, Hiroomi; Takano, Tatsuya; Hashimoto, Shunichi; Ikegami, Shiro; Fujita, Kagari; et al.

CS Fac. Pharm. Sci., Teikyo Univ., Sagamiko, 199-01, Japan

SO Trends Pharmacol. Res. Platelet Act. Factor (PAF) Jpn., Proc. Symp. Probl. PAF, 11th (1988), Meeting Date 1987, 138-46. Editor(s): Ogura, Yasumi; Kisara, Kensaku. Publisher: Ishiyaku EuroAmerica, Tokyo, Japan.

CODEN: 56ULA2

DT Conference

LA English

CC 15-3 (Immunochemistry)

AB Specific antibodies to platelet-activating factor (PAF) were prepared by immunizing rabbits with a hapten-bovine serum albumin (BSA) conjugate. As hapten a synthetic PAF derivative was used which is resistant to enzymic inactivation by plasma or tissues and which can bind to BSA through covalent bonding at the ω -position of the alkyl side chain. Antibody activity was determined by ELISA. Anti-PAF IgG reacted strongly with PAF. By means of the ELISA inhibition assay, antibodies did not cross-react with phosphocholine glycerophosphocholine, dilaurylglycerophosphocholine, or PAF analogs which have ethanolamine-type polar head groups instead of choline groups. The monoclonal antibodies were also produced in Balb/c mouse using the same immunizing method. When PAF was incubated with monoclonal antibodies and protein A Sepharose, supernatant did not cause rabbit platelet aggregation. The specificity and sensitivity of the mouse monoclonal antibodies were compared with those of rabbit polyclonal antibodies.

ST platelet activating factor antibody

IT Immunoglobulins

RL: FORM (Formation, nonpreparative)
(G, formation of, to platelet-activating factor, synthetic hapten induction of)

IT Antibodies

RL: FORM (Formation, nonpreparative)
(monoclonal, formation of, to platelet-activating factor, synthetic hapten induction of)

IT 65154-06-5, Blood platelet-activating factor

RL: BIOL (Biological study)
(antibodies to, synthetic analog hapten in formation of)

IT 130126-32-8

RL: BIOL (Biological study)
(as hapten for antibody formation to platelet-activating factor)

ANSWER 7 OF 20 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1989:91686 CAPLUS

DN 110:91686

ED Entered STN: 17 Mar 1989

TI Antigenic analogs of platelet-activating factor (PAF), production of the analogs and antibodies to them, and PAF immunoassays

IN Baldo, Brian Angelo; Redmond, John William

PA University of Sydney, Australia; Macquarie University; Royal North Shore Hospital

SO PCT Int. Appl., 46 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07F009-10

ICS G01N033-92; C07K015-12

CC 9-10 (Biochemical Methods)

Section cross-reference(s): 7, 23, 29

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8705904	A1	19871008	WO 1987-AU84	19870324 <--
	W: AU, JP, KR, US RW: DE, FR, GB, IT				
	AU 8772097	A1	19871020	AU 1987-72097	19870324 <--
	AU 607698	B2	19910314		
	EP 299965	A1	19890125	EP 1987-902318	19870324 <--
	R: DE, FR, GB, IT				
	JP 01502584	T2	19890907	JP 1987-502157	19870324 <--
	IL 82057	A1	19941111	IL 1987-82057	19870331 <--
	US 5061626	A	19911029	US 1987-156923	19871124 <--
PRAI	AU 1986-5175	A	19860324		
	WO 1987-AU84	A	19870324		

CLASS

	PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
	WO 8705904	ICM	C07F009-10
		ICS	G01N033-92; C07K015-12
		IPCI	C07F0009-10 [ICM,4]; C07F0009-00 [ICM,4,C*]; G01N0033-92 [ICS,4]; C07K0015-12 [ICS,4]
		IPCR	A61K0039-00 [N,A]; A61K0039-00 [N,C*]; C07F0009-00 [I,C*]; C07F0009-10 [I,A]; C07K0001-00 [I,C*]; C07K0001-107 [I,A]; C07K0016-18 [I,A]; C07K0016-18 [I,C*]; G01N0033-86 [I,A]; G01N0033-86 [I,C*]
	AU 8772097	IPCI	C07F0009-10 [ICM,4]; C07F0009-00 [ICM,4,C*]; G01N0033-92 [ICS,4]; C07K0015-12 [ICS,4]
		IPCR	A61K0039-00 [N,A]; A61K0039-00 [N,C*]; C07F0009-00 [I,C*]; C07F0009-10 [I,A]; C07K0001-00 [I,C*]; C07K0001-107 [I,A]; C07K0016-18 [I,A]; C07K0016-18 [I,C*]; G01N0033-86 [I,A]; G01N0033-86 [I,C*]
	EP 299965	IPCI	C07F0009-10 [ICM,4]; C07F0009-00 [ICM,4,C*]; G01N0033-92 [ICS,4]; C07K0015-12 [ICS,4]
		IPCR	A61K0039-00 [N,A]; A61K0039-00 [N,C*]; C07F0009-00 [I,C*]; C07F0009-10 [I,A]; C07K0001-00 [I,C*]; C07K0001-107 [I,A]; C07K0016-18 [I,A]; C07K0016-18 [I,C*]; G01N0033-86 [I,A]; G01N0033-86 [I,C*]
	JP 01502584	IPCI	C07F0009-10 [ICM,4]; C07F0009-00 [ICM,4,C*]; A61K0039-395 [ICS,4]; C07K0003-08 [ICS,4]; C07K0015-12 [ICS,4]; G01N0033-53 [ICS,4]
	IL 82057	IPCI	C07K0015-06 [ICM,5]; C07K0007-00 [ICS,5]; C07H0005-06 [ICS,5]; C07H0005-00 [ICS,5,C*]; C07F0009-10 [ICS,5]; C07F0009-00 [ICS,5,C*]; C08B0037-00 [ICS,5]; G01N0033-53 [ICS,5]
	US 5061626	IPCI	C12N0011-00

IPCR A61K0039-00 [N,A]; A61K0039-00 [N,C*]; C07F0009-00 [I,C*]; C07F0009-10 [I,A]; C07K0001-00 [I,C*]; C07K0001-107 [I,A]; C07K0016-18 [I,A]; C07K0016-18 [I,C*]; G01N0033-86 [I,A]; G01N0033-86 [I,C*]
 NCL 435/174.000; 435/192.000; 435/199.000; 435/207.000;
 436/545.000; 436/546.000; 530/345.000; 530/402.000;
 530/403.000; 530/404.000; 530/406.000; 530/408.000;
 530/409.000; 530/410.000; 554/080.000; 558/169.000;
 558/172.000

OS MARPAT 110:91686
 GI



AB PAF analogs I [R1 = C2-25 alkylene or alkenylene linking group substituted by radioactive I and X = H; or R1 = C2-25 alkylene, alkenylene, alkynylene, optionally 3H- or radioactive I-substituted, and X = CHO, di(C1-6 alkoxy)methyl, CO2H, NCO, OH, SH, N-(C1-6 alkyl)amino, N,N-di(C1-6 alkyl)amino, AB; A = linking group (NR6, CO2, O2C, CONR6, NR6CO, NHCSNH, SS; R6 = H, C1-6 alkyl); B = protein, peptide, carbohydrate, lipid of ≥ 2000 mol. weight, label; R2-R5 = C1-6 alkyl] are prepared and are useful in production of anti-PAF antibodies or as reagents in PAF immunoassays. 2-O-Acetyl-1-O-(6'-oxohexyl)-sn-glyceryl-3-phosphorylcholine [prepared from cyclohexanone and HC(OMe)3 in 8 steps] was conjugated to methylated bovine serum albumin. The conjugate was used to prepare rabbit anti-PAF serum which was used in an assay for PAF.

ST platelet activating factor analog antibody immunoassay; acetyloxohexylglycerylphosphorylcholine albumin conjugate; phosphorylcholine acetyloxohexylglyceryl albumin conjugate

IT Veterinary medicine (blood platelet-activating factor determination by immunoassay in relation to)

IT Blood analysis Body fluid (blood platelet-activating factor determination in, by immunoassay, antigenic and labeled analogs for)

IT Detergents Lecithins Ethers, uses and miscellaneous Polyoxyalkylenes, uses and miscellaneous RL: ANST (Analytical study) (in blood platelet-activating factor determination in body fluid by immunoassay)


IT Antibodies RL: ANST (Analytical study) (to blood platelet-activating factor analogs)

IT Ethers, biological studies RL: USES (Uses) (Ph, in blood platelet-activating factor determination in body fluid by immunoassay)

IT Carbohydrates and Sugars, compounds

IPCR A61K0039-00 [N,A]; A61K0039-00 [N,C*]; C07F0009-00 [I,C*]; C07F0009-10 [I,A]; C07K0001-00 [I,C*]; C07K0001-107 [I,A]; C07K0016-18 [I,A]; C07K0016-18 [I,C*]; G01N0033-86 [I,A]; G01N0033-86 [I,C*]
 NCL 435/174.000; 435/192.000; 435/199.000; 435/207.000; 436/545.000; 436/546.000; 530/345.000; 530/402.000; 530/403.000; 530/404.000; 530/406.000; 530/408.000; 530/409.000; 530/410.000; 554/080.000; 558/169.000; 558/172.000

OS MARPAT 110:91686
 GI



AB PAF analogs I [R1 = C2-25 alkylene or alkenylene linking group substituted by radioactive I and X = H; or R1 = C2-25 alkylene, alkenylene, alkynylene, optionally 3H- or radioactive I-substituted, and X = CHO, di(C1-6 alkoxy)methyl, CO2H, NCO, OH, SH, N-(C1-6 alkyl)amino, N,N-di(C1-6 alkyl)amino, AB; A = linking group (NR6, CO2, O2C, CONR6, NR6CO, NHCSNH, SS; R6 = H, C1-6 alkyl); B = protein, peptide, carbohydrate, lipid of ≥ 2000 mol. weight, label; R2-R5 = C1-6 alkyl] are prepared and are useful in production of anti-PAF antibodies or as reagents in PAF immunoassays. 2-O-Acetyl-1-O-(6'-oxohexyl)-sn-glyceryl-3-phosphorylcholine [prepared from cyclohexanone and HC(OMe)3 in 8 steps] was conjugated to methylated bovine serum albumin. The conjugate was used to prepare rabbit anti-PAF serum which was used in an assay for PAF.

ST platelet activating factor analog antibody immunoassay; acetyloxohexylglycerylphosphorylcholine albumin conjugate; phosphorylcholine acetyloxohexylglyceryl albumin conjugate

IT Veterinary medicine (blood platelet-activating factor determination by immunoassay in relation to)

IT Blood analysis Body fluid (blood platelet-activating factor determination in, by immunoassay, antigenic and labeled analogs for)

IT Detergents Lecithins Ethers, uses and miscellaneous Polyoxyalkylenes, uses and miscellaneous RL: ANST (Analytical study) (in blood platelet-activating factor determination in body fluid by immunoassay)

IT Antibodies RL: ANST (Analytical study) (to blood platelet-activating factor analogs)

IT Ethers, biological studies RL: USES (Uses) (Ph, in blood platelet-activating factor determination in body fluid by immunoassay)

IT Carbohydrates and Sugars, compounds

RL: ANST (Analytical study)
(acetals, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Carbohydrates and Sugars, esters
RL: ANST (Analytical study)
(alditols, anhydro, esters, with fatty acids, alkyl ethers, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Castor oil
RL: ANST (Analytical study)
(alkoxylated, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Albumins, compounds
Carbohydrates and Sugars, compounds
Lipids, compounds
Peptides, compounds
Proteins, specific or class
RL: ANST (Analytical study)
(conjugates, with glycerylphosphorylcholine derivative, as antigenic blood **platelet-activating factor** analogs)

IT Enzymes
RL: ANST (Analytical study)
(conjugates, with glycerylphosphorylcholine derivs., as labeled blood **platelet-activating factor** analogs)

IT Fatty acids, esters
RL: ANST (Analytical study)
(esters, with hexitol anhydrides, alkyl ethers, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Carbohydrates and Sugars, esters
RL: ANST (Analytical study)
(hexitols, anhydro, esters, with fatty acids, alkyl ethers, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Alcohols, compounds
RL: ANST (Analytical study)
(long-chain, alkoxylated, acetals, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Antibodies
RL: ANST (Analytical study)
(monoclonal, to blood **platelet-activating factor** analogs)

IT Detergents
(nonionic, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT 25104-18-1D, Polylysine, glycerylphosphorylcholine derivative conjugates
38000-06-5D, Polylysine, glycerylphosphorylcholine derivative conjugates
119142-22-2D, albumin and polylysine conjugates
RL: ANST (Analytical study)
(as antigenic blood **platelet-activating factor** analogs)

IT 9005-64-5, Tween 20
RL: ANST (Analytical study)
(blood **platelet-activating factor** acetylhydrolase inactivation by, blood **platelet-activating factor** immunoassay in relation to)

IT 51-45-6D, 1H-Imidazole-4-ethanamine, iodine-125-labeled 51-67-2D,
iodine-125-labeled 1080-06-4D, iodine-125-labeled
RL: ANST (Analytical study)
(blood **platelet-activating factor** analogs labeled with, for immunoassay)

IT 65154-06-5, Blood **platelet-activating factor**
RL: ANT (Analyte); ANST (Analytical study)
(determination of, by immunoassay, antigenic and labeled analogs for)

IT RL: ANST (Analytical study)
(acetals, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Carbohydrates and Sugars, esters
RL: ANST (Analytical study)
(alditols, anhydro, esters, with fatty acids, alkyl ethers, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Castor oil
RL: ANST (Analytical study)
(alkoxylated, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Albumins, compounds
Carbohydrates and Sugars, compounds
Lipids, compounds
Peptides, compounds
Proteins, specific or class
RL: ANST (Analytical study)
(conjugates, with glycerylphosphorylcholine derivative, as antigenic blood **platelet-activating factor** analogs)

IT Enzymes
RL: ANST (Analytical study)
(conjugates, with glycerylphosphorylcholine derivs., as labeled blood **platelet-activating factor** analogs)

IT Fatty acids, esters
RL: ANST (Analytical study)
(esters, with hexitol anhydrides, alkyl ethers, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Carbohydrates and Sugars, esters
RL: ANST (Analytical study)
(hexitols, anhydro, esters, with fatty acids, alkyl ethers, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Alcohols, compounds
RL: ANST (Analytical study)
(long-chain, alkoxylated, acetals, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT Antibodies
RL: ANST (Analytical study)
(monoclonal, to blood **platelet-activating factor** analogs)

IT Detergents
(nonionic, in blood **platelet-activating factor** determination in body fluid by immunoassay)

IT 25104-18-1D, Polylysine, glycerylphosphorylcholine derivative conjugates
38000-06-5D, Polylysine, glycerylphosphorylcholine derivative conjugates
119142-22-2D, albumin and polylysine conjugates
RL: ANST (Analytical study)
(as antigenic blood **platelet-activating factor** analogs)

IT 9005-64-5, Tween 20
RL: ANST (Analytical study)
(blood **platelet-activating factor** acetylhydrolase inactivation by, blood **platelet-activating factor** immunoassay in relation to)

IT 51-45-6D, 1H-Imidazole-4-ethanamine, iodine-125-labeled 51-67-2D,
iodine-125-labeled 1080-06-4D, iodine-125-labeled
RL: ANST (Analytical study)
(blood **platelet-activating factor** analogs labeled with, for immunoassay)

IT 65154-06-5, Blood **platelet-activating factor**
RL: ANT (Analyte); ANST (Analytical study)
(determination of, by immunoassay, antigenic and labeled analogs for)

IT 108-95-2D, Phenol, alkyl ethers
RL: ANST (Analytical study)
(in blood **platelet-activating factor**
determination in body fluid by immunoassay)

IT 76901-00-3, **Platelet activating factor**
acetylhydrolase
RL: ANST (Analytical study)
(inactivation of, by Tween 20, blood **platelet-activating factor** immunoassay in relation to)

IT 931-56-6P, 1-Methoxycyclohexane 933-40-4P, 1,1-Dimethoxycyclohexane
18751-83-2P, 6,6-Dimethoxyhexan-1-ol 25176-55-0P, Methyl-6,6-dimethoxyhexanoate 119142-18-6P 119142-19-7P 119142-20-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of blood **platelet-activating factor** analogs)

IT 119142-21-1DP, methylated albumin conjugates
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as immunogen for blood **platelet-activating factor** immunoassay)

IT 108-94-1, Cyclohexanone, reactions 149-73-5, Trimethylorthoformate
119142-17-5, (R)-1-(Benzylxy)-2,3-epoxypropane
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of blood **platelet-activating factor** analogs)

IT 108-95-2D, Phenol, alkyl ethers
RL: ANST (Analytical study)
(in blood platelet-activating factor
determination in body fluid by immunoassay)

IT 76901-00-3, Platelet activating factor
acetylhydrolase
RL: ANST (Analytical study)
(inactivation of, by Tween 20, blood platelet-
activating factor immunoassay in relation to)

IT 931-56-6P, 1-Methoxycyclohexane 933-40-4P, 1,1-Dimethoxycyclohexane
18751-83-2P, 6,6-Dimethoxyhexan-1-ol 25176-55-0P, Methyl-6,6-
dimethoxyhexanoate 119142-18-6P 119142-19-7P 119142-20-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and reaction of, in preparation of blood platelet-
activating factor analogs)

IT 119142-21-1DP, methylated albumin conjugates
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as immunogen for blood platelet-
activating factor immunoassay)

IT 108-94-1, Cyclohexanone, reactions 149-73-5, Trimethylorthoformate
119142-17-5, (R)-1-(Benzylxy)-2,3-epoxypropane
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, in preparation of blood platelet-activating
factor analogs)